Balloon Angioplasty is a procedure to enlarge the opening in a blood vessel that has become narrowed or blocked by plaque (a buildup of fat and cholesterol on the inner wall of the blood vessel). A small balloon is filled with air inside the blood vessel to push the plaque against the blood vessel wall and increase the opening.
The Ellipsys Vascular Access System reduces the time before patients with kidney failure can start lifesaving dialysis treatments, while requiring fewer secondary procedures, according to a new study led by interventional radiologist Jeffrey Hull, M.D., of Richmond Vascular Center.
An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.
A new study shows significant benefits of the Ellipsys Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) patients who require hemodialysis.
Devices coated with a drug called paclitaxel that are used for widening blocked arteries in legs and feet are safe and not linked to an increase in deaths, according to a study of nearly 65,000 patients, published in the European Heart Journal today (Wednesday).
There was no time to spare when air passenger Hutz Hertzberg, DMin, PhD, suddenly collapsed at Midway Airport in full cardiac arrest.
Prediabetes, the precursor stage before type 2 diabetes, does not increase the cardiac risk of patients with coronary artery disease.
Drug-coated balloon catheters to open narrowed blood vessels and to deliver drugs to the impacted sites are used frequently for the treatment of peripheral arterial disease.
Scientists have found a potential new drug for treating the heart damage caused by a heart attack by targeting the way the heart reacts to stress.
Intact Vascular, Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, today announced it received U.S. Food and Drug Administration approval for the Tack Endovascular System, a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease.
Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that data from its Tack Optimized Balloon Angioplasty II pivotal clinical trial will be presented at the 15th Annual VIVA Conference in Las Vegas, NV on November 5-8.
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 203-214(12); DOI: https://doi.org/10.15212/CVIA.2017.0046 Ahmad A. Mahmoud, Ahmed N. Mahmoud, Akram Y. Elgendy and R. David Anderson from the Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL, USA consider the current status of coronary atherectomy.
A removable balloon is as good as a permanent stent implant for opening small blocked arteries, according to late breaking results from the BASKET-SMALL 2 trial presented in a Hot Line Session today at ESC Congress 2018 and simultaneously published in The Lancet.
Today, the U.S. Food and Drug Administration permitted marketing of two catheter-based devices designed to create a connection to veins and arteries in patients with chronic kidney disease who need hemodialysis.
The newer high-sensitivity troponin test discovers smaller amounts of heart-specific proteins, troponins, than the older troponin test and thus identifies more myocardial infarction patients than before.
Heart attack increased the risk of vascular dementia by 35 percent, and the risk remains elevated for up to 35 years after the heart attack.
A new gene therapy that targets the heart and requires only one treatment session has been found safe for patients with coronary artery disease, according to a successful trial carried out in Finland.
Royal Philips will showcase its market-leading image guided therapy solutions at EuroPCR 2017 (Paris, May 16 – 19, 2017) to advance interventional cardiology and make care more personalized, while optimizing patient care and hospital budgets. This year, the healthcare industry is celebrating the 40th anniversary of angioplasty, the minimally invasive treatment of obstructed blood vessels, and as a leader in interventional cardiology, Philips is reinforcing its longstanding commitment to transforming cardiac care with meaningful innovations.
If hospitals can perform more transradial, same-day percutaneous coronary intervention, or PCIs, not only will patients benefit because it is associated with have less complications, but collectively, hospitals across the U.S. could save $300 million each year, according to research published today in JACC: Cardiovascular Interventions.
Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to a broad report on trends in heart disease care from the American College of Cardiology's National Cardiovascular Data Registry published in the Journal of the American College of Cardiology.
Loyola Medicine will be among the first health systems in the country to offer heart patients a new stent that is absorbed by the body once it has served its purpose.